徐婧,陈发东,张奇

• 1:同济大学附属东方医院心内科

摘要(Abstract)：

<正>心房颤动(房颤)是常见的心律失常疾病之一,房颤导致的卒中并发症危害极大。有研究表明,每年非瓣膜型房颤患者(nonvalvular atrial fibrillation,NVAF)并发卒中的风险是非房颤人群的17.6倍左右[1]。房颤诱发的卒中,较继发于动脉粥状硬化性脑血管病所诱发的卒中,具有梗死面积更大、致残率更高、死亡率更高、预后更差等特点[2-3]。除了传统的抗

关键词(KeyWords)： 左心耳封堵;内皮化

Abstract:

Keywords:

基金项目(Foundation): 上海市浦东新区卫生系统重点学科群建设资助(PWZxq2017-05)

作者(Author): 徐婧,陈发东,张奇

参考文献(References)：

• [1]Schnabel RB,Yin X,Gona P,et al.50 year trends in atrial fibrillation prevalence,incidence,risk factors,and mortality in the Framingham Heart Study:a cohort study.Lancet,2015,386(9989):154-162.
• [2]Sharma M,Cornelius VR,Patel JP,et al.Effi cacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fi brillation and secondary prevention of venous thromboembolism:systematic review and meta-analysis.Circulation,2015,132(3):194-204.
• [3]Reddy VY,Gibson DN,Kar S,et al.Post-approval U.S.experience with left atrial appendage closure for stroke prevention in atrial fi brillation.J Am Coll Cardiol,2017,69(3):253-261.
• [4]江立生，何奔.“PROTECT AF研究”和“PREVAIL研究”5年随访结果看左心耳封堵所面临的质疑与挑战.中国介入心脏病学杂志，2018,26(10):597-600.
• [5]熊婧，陈维.经皮左心耳封堵术研究回顾与展望.中国介入心脏病学杂志，2018,26(10):589-592.
• [6]Reddy VY,Doshi SK,Kar S,et al.5-year outcomes after left atrial appendage closure:from the PREVAIL and PROTECT AF trials.JAm Coll Cardiol,2017,70(24):2964-2975.
• [7]Holmes DR,Reddy VY,Gordon NT,et al.Long-term safety and efficacy in continued access left atrial appendage closure registries.JAm Coll Cardiol,2019,74(23):2878-2889.
• [8]Main ML,Fan D,Reddy VY,et al.Assessment of device-related thrombus and associate clinical outcomes with the WATCHMANleft atrial appendag closure device for embolic protection in patients with atrial fi brillation(from the PROTECT-AF trial).Am J Cardiol,2016,117(7):1127-1134.
• [9]Dukkipati SR,Kar S,Holmes DR,et al.Device-related thrombus af ter lef t atrial appendage closure.Circulation,2018,138(9):874-885.
• [10]Fauchier L,Cinaud A,Brigadeau F,et al.Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fi brillation.J Am Coll Cardiol,2018,71(14):1528-1536.
• [11]Yu J,Bai Y,Muenzel M,et al.Device-related thrombus after left atrial appendage closure:A 4-year retrospective analysis from a realworld setting.J Am Coll Cardiol,2017,70(18):B258.
• [12]Lammers J,Elenbaas T,Meijer A.Thrombus formation on an Amplatzer closure device after left atrial appendage closure.Eur Heart J,2013,34(10):741.
• [13]Schwartz RS,Holmes DR,Van Tassel RA,et al.Left atrial appendage obliteration.Mechanisms of healing and intracardiac integration.JACC Cardiovasc Interv,2010,3(8):870-877.
• [14]Sinno H,Prakash S.Complements and the wound healing cascade:an updated review.Plast Surg Int,2013,2013:146764.
• [15]Reinke JM,Sorg H.Wound repair and regeneration.Eur Surg Res,2012,49(1):35-43.
• [16]Tang X,Zhang Z,Wang F,et al.Percutaneous left atrial appendage closure with LACBES?occluder-a preclinical feasibility study.Circ J,2017,82(1):87-92.
• [17]Kar S,Hou D,Jones R,et al.Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model.JACC Cardiovasc Interv,2014,7(7):801-809.
• [18]Massarenti L,Yilmaz A.Incomplete endothelialization of left atrial appendage occlusion device 10 months after implantation.JCardiovasc Electrophysiol,2012,23(12):1384-1385.
• [19]Sharma SP,Singh D,Nakamura D,et al.Incomplete endothelialization of WatchmanTM device:predictors and implications from two cases.J Atr Fibrill,2019,11(5):2162.
• [20]Granier M,Laugaudin G,Massin F,et al.Occurrence of incomplete endothelialization causing residual permeability after left atrial appendage closure.J Invasive Cardiol,2018,30(7):245-250.
• [21]Suwalski P,Witkowska A,Drobiński D,et al.Stand-alone totally thoracoscopic left atrial appendage exclusion using a novel clipping system in patients with high risk of stroke-initial experience and literature review.Kardiochir Torakchirurgia Pol,2015,12(4):298-303.
• [22]Saw J,Tzikas A,Shakir S,et al.Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug.JACC Cardiovasc Interv,2017,10(4):391-399.
• [23]Reddy VY,Doshi SK,Sievert H,et al.Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation:2.3-year follow-up of the PROTECT AF(Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation)trial.Circulation,2013,127(6):720-729．
• [24]Bai Y,Xue X,Duenninger E,et al.Real-world survival data of device-related thrombus following left atrial appendage closure:4-year experience from a single center.Heart Vessels,2019,34(8):1360-1369.
• [25]Prosperi-Porta G,Schnell G,Colbert J,et al.Multiple thromboembolic events from a left atrial appendage occlusion device.Can J Cardiol,2018,34(3):342.e13-342.e15.
• [26]Sinanis T.A very late and persistent thrombosis after left atrial appendage occlusion.Heart Views,2019,20(4):175-177.
• [27]Boersma LV,Ince H,Kisrhe S,et al.Evaluating real-world clinical outcomes in atrial fi brillation patients receiving the WATCHMAN left atrial appendage closure technology.Circ Arrhythm Electrophysiol,2019,12(4):e006841.
• [28]Meier B,Blaauw Y,Khattab AA,et al.EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion.Euro Intervention,2015,10(9):1109-1125.
• [29]PracońR,Demkow M.How to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion.Postep Kardiol Inter,2015,11(1):5-8.
• [30]中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，心房颤动防治专家工作委员会，等.左心耳干预预防心房颤动患者血栓栓塞事件：目前的认识和建议(2019).中华心律失常学杂志，2019,23(5):372-392.
• [31]Saw J,Fahmy P,De Jong P,et al.Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure.Eur Heart J Cardiovasc Imaging,2015,16(11):1198-1206.
• [32]Homsi R,Nath B,Luetkens JA,et al.Can contrast-enhanced multi-detector computed tomography replace transesophageal echocardiography for the detection of thrombogenic milieu and thrombi in the left atrial appendage:a prospective study with 124patients.Rofo,2016,188(1):45-52.
• [33]Sivasambu B,Arbab-Zadeh A,Hays A,et al.Delayed endothelialization of watchman device identif ied with cardiac CT.J Cardiovasc Electrophysiol,2019,30(8):1319-1324.
• [34]Granier M,Laugaudin G,Massin F,et al.Occurrence of incomplete endothelialization causing residual permeability after left atrial appendage closure.J Invasive Cardiol,2018,30(7):245-250.
• [35]Qamar SR,Jalal S,Nicolaou S,et al.Comparison of cardiac computerized tomography angiography and transesophageal echocardiography for device surveillance after endovascular left atrial appendage closure.Euro Intervention,2019,15(8):663-670.
• [36]?ahin DA,Ba?p?nar O,SülüA,et al.A comparison of the in vivo neoendothelialization and wound healing processes of three atrial septal defect occluders used during childhood in a nonrandomized prospective trial.Anatol J Cardiol,2017,18(3):229-234.
• [37]Scicchitano P,Gesualdo M,Cortese F,et al.Atrial septal defect and patent foramen ovale:early and long-term eff ects on endothelial function after percutaneous occlusion procedure.Heart Vessels,2019,34(9):1499-1508.
• [38]Xu MG,Meng XC,Li BN,et al.The circulating level of endothelial progenitor cells after transcatheter closure of congenital heart disease in children.Pediatr Cardiol,2013,34(6):1344-1349.
• [39]Mochizuki M,Gü?E,Park AJ,et al.Growth factors with enhanced syndecan binding generate tonic signalling and promote tissue healing.Nat Biomed Eng,2020,4(4):463-475.
• [40]Wang L,Yue Y,Yang X,et al.Platelet derived growth factor alpha(PDGFRα)induces the activation of cardiac fi broblasts by activati ng c-Kit.Med Sci Monit,2017,23:3808-3816.
• [41]Schütz E,Bochenek ML,Riehl DR.Absence of thansforming growth factor beta 1 in murine plateletsreduces neointima formation without aff ecting arterial thrombosis.Thromb Haemost,2017,117(9):1782-1797.
• [42]Sevostyanova VV,Antonova LV,Velikanova EA,et al.Endothelialization of polycaprolactone vascular graft under the action of locally applied vascular endothelial growth factor.Bull Exp Biol Med,2018,165(2):264-268.
• [43]Fan Z,Xu Z,Niu H,et al.Spatiotemporal delivery of basic fibroblast growth factor to directly and simultaneously attenuate cardiac fi brosis and promote cardiac tissue vascularization following myocardial infarction.J Control Release,2019,311-312:233-244.
• [44]Nguyen TT,Jones JI,Wolter WR,et al.Hyperbaric oxygen therapy accelerates wound healing in diabetic miceby decreasing active m atrix metalloproteinase-9.Wound Repair Regen,2020,28(2):194-201.
• [45]Liang Y,Yang C,Lin Y,et al.Matrix metalloproteinase 9 induces keratinocyte apoptosis through Fas L/Fas pathway in diabetic wound.Apoptosis,2019,24(7-8):542-551.
• [46]Ye YZ,Chang YF,Wang BZ,et al.Prognostic value of von Willebrand factor for patients with atrial fibrillation:a metaanalysis of prospective cohort studies.Postgrad Med J,2020,96(1135):267-276.
• [47]Gragnano F,Golia E,Natale F,et al.Von Willebrand factor and ca rdiovascular disease:from a biochemical marker to an attractive ther apeutic target.Curr Vasc Pharmacol,2017,15(5):404-415.2019-12-16